At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Zoledronate +1 moredrug
Likely dose
Zoledronate 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bone-Targeted Therapy Combining Zoledronate With Atorvastatin in Renal Cell Carcinoma: A Phase II Study
In Brief
A Phase 2 clinical trial evaluating Zoledronate and Atorvastatin for Kidney Cancer and Renal Cell Carcinoma. Completed, enrolled 11 participants across 1 site.
Detailed Summary
Objectives: Primary: Evaluate clinical outcome based on the time to skeletal events after bone-targeted therapy Secondary: 1. Evaluate clinical outcome based on the presence of calcification at the site of osteolytic metastases 2. Measure bone-formation and resorption markers at baseline and during bone-targeted therapy. 3. Assess effect of the bone-targeted regimen on serum cholesterol levels
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer, Renal Cell Carcinoma
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedJun 2007
Primary CompletionJan 2012
TodayJul 2026
First PostedJun 25, 2007
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.0 years ago
Interventions
Zoledronatedrug
4 mg IV Once Every 4 Weeks
Atorvastatindrug
20 mg PO Daily